Treatment

England’s National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of Mavenclad (cladribine) in people with aggressive relapsing-remitting multiple sclerosis (RRMS) in ways that should help eligible patients be able to access the medication sooner. The new guidelines have less stringent…

A large proportion of people with multiple sclerosis (MS) experience headaches as a result of their condition, and treatment with interferon-based therapies seems to increase the risk of worsening headaches or developing new ones, a study found. In contrast, the CD20 antibody rituximab that’s used off-label in MS…

Resistance training by middle-aged people with multiple sclerosis (MS) was linked with significant improvements in muscle strength in a recent meta-analysis of previous clinical trial data. The analysis indicated the benefits of such training, which is designed to boost strength and endurance, were more variable in fatigue and quality…

Helius Medical Technologies said it has a booth at a meeting for multiple sclerosis (MS) professionals to showcase its PoNS device and the progress made over the last year in providing access to the neuromodulation device, which is designed to improve walking ability in people with MS.

Progentos Therapeutics said it received $65 million in funding to support the development of myelin regeneration medications able to restore function in people with multiple sclerosis (MS) and other diseases marked by myelin loss. The biotech company said it will use the funds to advance its MS program…

A Marquette University team is leading a new project that will combine balance and cardio training with the goal of improving the walking abilities of people with multiple sclerosis (MS). Led by Marquette biomedical engineering professor Brian Schmit, PhD, the project — which is supported by a $3.34 million…

People with multiple sclerosis (MS) who start treatment with a mild-to-moderate efficacy disease-modifying therapy (DMT) were more likely to switch to another DMT, an analysis of the German MS Registry finds. Starting a DMT between 2014 and 2017 was also a predictor of switching. Disease activity despite treatment…

Alternative splicing, a biological process that allows a single gene to code for multiple proteins, is extensively disrupted in immune cells isolated from untreated multiple sclerosis (MS) patients, and long-term treatment with interferon beta-based therapies largely corrects the defects, a study found. “Alternative splicing is a potential biomarker warning…

A small molecule called ESI1 stimulated the repair of the myelin sheath, the fatty coating on nerve fibers that is damaged in multiple sclerosis (MS), a study found. In an MS mouse model, this resulted in improved motor function and nerve cell communication, as well as reduced signs…

The National Multiple Sclerosis Society has awarded Inflectis BioScience a grant valued at $649,601 to advance the preclinical development of IFB-048, the company’s experimental treatment to promote myelin repair in multiple sclerosis (MS). “This grant along with the support from the Society are a testimony…

A committee of the European Medicines Agency (EMA) is recommending the approval of a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) for people with multiple sclerosis (MS) in the European Union. The Committee for Medicinal Products for Human Use, known as CHMP, specifically recommended that this new formulation…

NKTR-0165, an antibody that targets the tumor necrosis factor receptor type 2 (TNFR2), will continue to be developed by Nektar Therapeutics as a candidate for treating multiple sclerosis (MS) and other autoimmune diseases. The experimental therapy was developed under a 2021 collaboration between Nektar and Biolojic…

A lower dose of the experimental oral therapy vidofludimus calcium (IMU-838) was not as effective as higher doses at reducing lesions in people with relapsing-remitting multiple sclerosis (RRMS), extended data from the therapy’s Phase 2 EMPhASIS trial show. “We found that doses of 30 mg and 45 mg,…

People with multiple sclerosis (MS) who are being treated with Tysabri (natalizumab) tend to prefer receiving the medication as a subcutaneous (under-the-skin) injection rather than an intravenous (into-the-vein) infusion, according to new data from an observational study. “Based on current data, there is a trend toward patients’ preference…

Fully 70% of patients with nonactive secondary progressive multiple sclerosis (SPMS) who received foralumab nasal spray in an expanded access program (EAP) experienced a lessening in fatigue levels after six months of treatment. That’s according to early findings from the EAP — a program that enables patients with serious…

A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain free of clinical relapses and new or worsening brain lesions, according to one-year data from the Phase 3 OCARINA II study. Given twice a year as a 10-minute injection, this formulation of Ocrevus…

Viatris has launched a generic version of low-dose Copaxone (glatiramer acetate) in the Canadian market for the treatment of people with relapsing-remitting multiple sclerosis (RRMS) who retain the ability to walk. Called Glatiramer Acetate Injection 20 mg/mL, the product was approved in Canada as a generic of…

Two years of treatment with Briumvi (ublituximab) in clinical trials resulted in a confirmed reduction in disability for more than 1 in 10 people with early relapsing multiple sclerosis (MS) who had not received any prior treatment. That’s according to new data from the ULTIMATE Phase 3 trials,…

Ocrevus (ocrelizumab) continued to prevent disability progression among people with relapsing and progressive forms of multiple sclerosis (MS) over 10 years, according to clinical trial analyses. The most pronounced benefits were observed in patients who started on the therapy in the controlled part of the trials, compared with…

For people recently diagnosed with multiple sclerosis (MS), first-line treatment with Kesimpta (ofatumumab) was associated with a lower risk of disability progression over starting it after about 2.5 years of using Aubagio (teriflunomide). That’s according to six years of data spanning the ASCLEPIOS I (NCT02792218) and…

Long-term treatment with Clene Nanomedicine‘s experimental oral therapy CNM-Au8 led to signs of sustained improvements in nerve and myelin health for people with relapsing-remitting multiple sclerosis (RRMS) over three years, according to new data from the VISIONARY-MS clinical trial. The findings continue to support Clene’s plans to…

A stem cell transplant effectively reduced the abnormal immune response that drives multiple sclerosis (MS) progression by altering a specific group of immune cells called myeloid cells, a mouse study showed. Treatment with a compound that suppressed a receptor called CSF1R improved the transplantation efficiency of myeloid cells…

Researchers have identified three distinct immune signatures in the blood of people with early multiple sclerosis (MS) that seem to be linked to specific disease trajectories and response to treatment, potentially offering a path to personalized care. “These findings represent a pivotal shift towards precision medicine in MS,” Heinz Wiendl,…

The prescribing label for Mavenclad (cladribine) in Great Britain has been extended to include the treatment of adults with active relapsing forms of multiple sclerosis (MS), as defined by clinical or imaging features. This decision made the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) the first to…

The Swank and Wahls diets, which are used by people with multiple sclerosis (MS), were associated with improvements in cognition and fatty acid blood profiles in relapsing-remitting MS (RRMS) patients, according to new analyses from the WAVES trial. Changes in omega-3 fatty acids after about three months correlated…

Kyverna Therapeutics‘ cell-based therapy KYV-101 had an acceptable safety profile and promising treatment effects when given to two people with hard-to-treat progressive multiple sclerosis (MS), according to a case study. “We are very pleased about offering this potentially paradigm-shifting treatment opportunity to patients that have exhausted other medical…

FSD Pharma has entered an agreement to launch a Phase 1 clinical trial that will test multiple ascending doses of Lucid-21-302 — an oral treatment candidate commonly known as Lucid-MS, for all types of multiple sclerosis (MS) — in healthy volunteers. The company’s subsidiary Huge Biopharma Australia established…

People who start treatment with Tysabri (natalizumab) soon after being diagnosed with multiple sclerosis (MS) are at a lower risk of relapse in the long term compared with patients who start on less effective disease-modifying therapies (DMT), a study has found. Patients on Tysabri, an antibody-based therapy,…

The French company Juvisé Pharmaceuticals has acquired the rights to develop and market the approved multiple sclerosis (MS) therapy Ponvory (ponesimod) outside the U.S. and Canada. The global rights were acquired from Actelion Pharmaceuticals, the therapy’s original developer and now part of Johnson & Johnson Innovative Medicine.

Multiple sclerosis (MS) patients diagnosed in more recent years — specifically after 2017 — were more likely to start sooner on a first MS disease-modifying therapy (DMT) than were those diagnosed between 2014 and 2016, an analysis of data from three large MS registries found. However, starting with…